- Home
- Products
- Customized ADCs
- HIV-1
- Anti-HIV-1 (Suvizumab)-MC-Vc-PAB-SN38 ADC
Anti-HIV-1 (Suvizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2112)
This ADC product is comprised of an anti-HIV-1 monoclonal antibody conjugated via a MC-Vc-PAB linker to SN38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SN-38 binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- HIV-1
- Alternative Names
- HIV-1
- Overview
- HIV is a highly variable virus which mutates very readily. This means there are many different strains of HIV, even within the body of a single infected person. The strains of HIV1 can be classified into three groups : the "major" group M, the "outlier" group O and the "new" group N. These three groups may represent three separate introductions of simian immunodeficiency virus into humans. Group O appears to be restricted to West-Central Africa and group N, discovered in 1998 in Cameroon, is extremely rare. More than 90% of HIV1 infections belong to HIV1 group M.
- Overview
- Humanized Anti-HIV-1 IgG1-kappa antibody, Suvizumab
- Generic name
- Suvizumab
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- SN-38 (7-ethyl-10-hydroxycamptothecin)
- Description
- SN38 (7-ethyl-10-hydroxy camptothecin) is an active metabolite of the cancer prodrug, irinotecan, with the ability of inhibiting Topoisomerase I, which is belong to the camptothecin family. SN-38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD33 (Lintuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-816)
- Anti-TNFRSF12 (Enavatuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-1899)
- Anti-CD3E (Ertumaxomab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2304)
- Anti-158P1D7 (clone Hal5-10acl2)-VC-MMAE ADC (CAT#: ADC-W-016)
- Anti-EGFL7 (Parsatuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1031)
- Anti-IGF1R (Dalotuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1265)
- Anti-EGFR (Matuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1038)
- Anti-FOLR1 (clone M9346A)-sulfo-SPDB-DM4 ADC (CAT#: ADC-W-402)
- Anti-IL6 (Olokizumab)-SPDB-DM4 ADC (CAT#: ADC-W-1419)
- Anti-IL1B (Canakinumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1339)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2112. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2113 | Anti-HIV-1 (Suvizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2108 | Anti-HIV-1 (Suvizumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2110 | Anti-HIV-1 (Suvizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2111 | Anti-HIV-1 (Suvizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2109 | Anti-HIV-1 (Suvizumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2601 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2623 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2587 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2602 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2581 | Anti-CEACAM5-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2563 | Anti-MSLN (Anetumab )-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2593 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2608 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2602 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2618 | Anti-MS4A1-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
